Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Sophia Frentz"'
Autor:
Sophia Frentz
Publikováno v:
Queering Science Communication ISBN: 9781529224436
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a618bdfffe09843648207c322954d96d
https://doi.org/10.56687/9781529224436-007
https://doi.org/10.56687/9781529224436-007
Autor:
Genevieve Dall, Karen Harris, Nonie Chan, Stephen J. Luen, Sophia Frentzas, Daphne Day, Michelle Barrett, Anna Kilgour, Mark Buzza
Publikováno v:
Current Oncology, Vol 31, Iss 8, Pp 4519-4530 (2024)
The Victorian Precision Oncology Summit, convened in 2023, was a joint initiative between the Victorian Comprehensive Cancer Centre Alliance (VCCC Alliance) and the Monash Partners Comprehensive Cancer Consortium (MPCCC) and was proposed to guide a c
Externí odkaz:
https://doaj.org/article/925a83d307a64d109d6bb755f122a7ca
Autor:
Asmerom T. Sengal, Vanessa Bonazzi, Deborah Smith, Cristian P. Moiola, Rohan Lourie, Rebecca Rogers, Eva Colas, Antonio Gil-Moreno, Sophia Frentzas, Naven Chetty, Lewis Perrin, Pamela M. Pollock
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-18 (2023)
Abstract Endometrial cancer (EC) patients with metastatic/recurrent disease have limited treatment options and poor survival outcomes. Recently, we discovered the FGFR2c splice isoform is associated with poor prognosis in EC patients. Here we report
Externí odkaz:
https://doaj.org/article/b9b1b53e0c77425bb2b8f73a70dc9aaa
Autor:
Wenjing Wang, Yu Xia, Charlotte Lemech, Adnan Nagrial, Baiyong Li, Zhongmin Maxwell Wang, Sophia Frentzas, Anna Rachelle Austria Mislang, Craig Underhill, Jermaine I G Coward
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
Background Studies showed that vascular endothelial growth factor (VEGF) inhibitors could improve therapeutic efficacy of PD-1/PD-L1 antibodies by transforming the immunosuppressive tumor microenvironment (TME) into an immunoresponsive TME. Ivonescim
Externí odkaz:
https://doaj.org/article/94eb2c1d24274681b9ae9f7010b69141
Autor:
Stephen P. Robertson, Zandra A. Jenkins, Tracy Dudding, Margriet van Kogelenberg, Alison Macharg, George McGillivray, Stuart Sugito, Jacek Pilch, Raj P. Kapur, Nicola Foulds, Sophia Frentz, Mark C. Hannibal, Cheng Yee Chang, Sixto García-Miñaur, Scott Nightingale, David Markie, Richard J. Leventer, Timothy R. Morgan, Wenhua Wei
Publikováno v:
Human Mutation. 39:103-113
Loss-of-function mutations in the X-linked gene FLNA can lead to abnormal neuronal migration, vascular and cardiac defects, and congenital intestinal pseudo-obstruction (CIPO), the latter characterized by anomalous intestinal smooth muscle layering.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4bb3aadd28906fd00206706b1af6d87
https://doi.org/10.1002/humu.23355
https://doi.org/10.1002/humu.23355
Autor:
Sophia Frentz, Jenny Morton, Stephen P. Robertson, Andrew J. Sutherland-Smith, Timothy R. Morgan
Publikováno v:
American Journal of Medical Genetics Part A. 170:2706-2710
Recently, a newly identified autosomal recessive skeletal dysplasia was described characterized by calvarial abnormalities (including cranium bifidum, coronal, and lambdoid synostosis), oligodactyly, femoral bowing, narrow thorax, small pelvic bones,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04b89bd9fffe907558edfb4003de30b0
https://doi.org/10.1002/ajmg.a.37804
https://doi.org/10.1002/ajmg.a.37804
Autor:
Andrew Haydon, John Powderly, Timothy Wyant, James Vasselli, Drew Rasco, Meredith McKean, Elizabeth Ahern, Sophia Frentzas, Andrew Weickhardt, Inbar Amit, Aron Knickerbocker, Yanay Ofran, Paul de Souza, Jenny Tang, Lori Richards
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/cac7820b4bd0445e9e32670fae38d1ab
Autor:
Wei Tan, Tarek Meniawy, Steven Kao, Nageshwar Budha, Sophia Frentzas, Hao Zheng, Rang Gao, Ahsan Rizwan, Luz de la Hoz Pedroza
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Background Ociperlimab, a novel, humanized monoclonal antibody (mAb), binds to T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) with high affinity and specificity. Tislelizumab is an anti-pr
Externí odkaz:
https://doaj.org/article/ee64015b8658483986a54fee5000268f
Autor:
Siddharth Menon, Amy Davies, Sophia Frentzas, Cheryl‐Ann Hawkins, Eva Segelov, Daphne Day, Ben Markman
Publikováno v:
Cancer Reports, Vol 5, Iss 2, Pp n/a-n/a (2022)
Abstract Background With the rapid influx of novel anti‐cancer agents, phase I clinical trials in oncology are evolving. Historically, response rates on early phase trials have been modest with the clinical benefit and ethics of enrolment debated.
Externí odkaz:
https://doaj.org/article/78eae5c9830d41b9a993510cdf6bab8c